How to avoid iatrogenic morbidity and mortality while increasing availability of oxytocin and misoprostol for PPH prevention

摘要: Abstract Objective Increased availability of oxytocin and misoprostol is needed to reduce the risk postpartum hemorrhage. This review compiles rates risks adverse maternal perinatal outcomes associated with use these medications for labor induction augmentation in low-income countries. Recommendations are proposed based on findings. Methods We did a structured literature using 5 databases followed by analysis from existing data. Results Combined were documented up 50% hospital-based deliveries identified databases. Data sparse but suggest associations between induction/augmentation stillbirth, neonatal resuscitation, uterine rupture, inappropriate administration both outside inside healthcare systems Conclusions Guidelines specifically low resourced settings. Rigorous studies should be pursued quantify magnitude effect morbidity mortality. Programs ensure community-wide awareness effects improper drugs mothers babies, especially out-of-hospital